Top

Published in:

Open Access 20-11-2023 | Cancer Therapy | REVIEW AND PERSPECTIVES

Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view

Authors: Jakob M. Riedl, Florian Moik, Tamara Esterl, Sarah M. Kostmann, Armin Gerger, Philipp J. Jost

Published in: Virchows Archiv | Issue 2/2024

Abstract

Medical oncology is rapidly evolving with the implementation of personalized, targeted therapies. Advances in molecular diagnostics and the biologic understanding of cancer pathophysiology led to the identification of specific genetic alterations as drivers of cancer progression. Further, improvements in drug development enable the direct interference with these pathways, which allow tailoring personalized treatments based on a distinct molecular characterization of tumors. Thereby, we are currently experiencing a paradigm-shift in the treatment of cancers towards cancer-type agnostic, molecularly targeted, personalized therapies. However, this concept has several important hurdles and limitations to overcome to ultimately increase the proportion of patients benefitting from the precision oncology approach. These include the assessment of clinical relevancy of identified alterations, capturing and interpreting levels of heterogeneity based on intra-tumoral or time-dependent molecular evolution, and challenges in the practical implementation of precision oncology in routine clinical care. In the present review, we summarize the current state of cancer-agnostic precision oncology, discuss the concept of molecular tumor boards, and consider current limitations of personalized cancer therapy. Further, we provide an outlook towards potential future developments including the implementation of functionality assessments of identified genetic alterations and the broader use of liquid biopsies in order to obtain more comprehensive and longitudinal genetic information that might guide personalized cancer therapy in the future.

Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL (2020) Molecular profiling for precision cancer therapies. Genome Med 12(1):8. https://doi.org/10.1186/s13073-019-0703-1CrossRefPubMedPubMedCentral

Wahida A, Buschhorn L, Fröhling S et al (2022) The coming decade in precision oncology: six riddles. Nat Rev Cancer 23(1):43–54. https://doi.org/10.1038/s41568-022-00529-3CrossRefPubMed

Brown NA, Elenitoba-Johnson KSJ (2020) Enabling precision oncology through precision diagnostics. Annu Rev Pathol 15:97–121. https://doi.org/10.1146/annurev-pathmechdis-012418-012735CrossRefPubMed

Mateo J, Steuten L, Aftimos P et al (2022) Delivering precision oncology to patients with cancer. Nat Med 28(4):658–665. https://doi.org/10.1038/s41591-022-01717-2CrossRefPubMed

Dugger SA, Platt A, Goldstein DB (2018) Drug development in the era of precision medicine. Nat Rev Drug Discov 17(3):183–196. https://doi.org/10.1038/nrd.2017.226CrossRefPubMed

Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372(9):793–795. https://doi.org/10.1056/NEJMp1500523CrossRefPubMedPubMedCentral

Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R (2020) Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 86:102019. https://doi.org/10.1016/j.ctrv.2020.102019CrossRefPubMedPubMedCentral

van der Velden DL, van Herpen CML, van Laarhoven HWM et al (2017) Molecular tumor boards: current practice and future needs. Ann Oncol 28(12):3070–3075. https://doi.org/10.1093/annonc/mdx528CrossRefPubMed

Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037. https://doi.org/10.1056/nejm200104053441401CrossRefPubMed

10.

Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. https://doi.org/10.1056/nejm200103153441101CrossRefPubMed

11.

Berger MF, Mardis ER (2018) The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol 15(6):353–365. https://doi.org/10.1038/s41571-018-0002-6CrossRefPubMedPubMedCentral

12.

Weinstein JN, Collisson EA, Mills GB et al (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113–1120. https://doi.org/10.1038/ng.2764CrossRefPubMedPubMedCentral

13.

Waarts MR, Stonestrom AJ, Park YC, Levine RL (2022) Targeting mutations in cancer. J Clin Invest 132:8. https://doi.org/10.1172/jci154943CrossRef

14.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275. Erratum in: Ann Oncol. 2019 May; 30(5):863–870

15.

Gutierrez ME, Price KS, Lanman RB, Nagy RJ, Shah I, Mathura S, Mulcahy M, Norden AD, Goldberg SL (2019) Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer. JCO Precis Oncol 3:PO.19.00274. https://doi.org/10.1200/po.19.00274

16.

Lamarca A, Edeline J, Goyal L (2022) How I treat biliary tract cancer. ESMO Open 7(1):100378. https://doi.org/10.1016/j.esmoop.2021.100378CrossRefPubMedPubMedCentral

17.

Looney A-M, Nawaz K, Webster RM (2020) Tumour-agnostic therapies. Nat Rev Drug Discov 19(6):383–385CrossRefPubMed

18.

Horak P, Leichsenring J, Goldschmid H et al (2022) Assigning evidence to actionability: an introduction to variant interpretation in precision cancer medicine. Genes Chromosom Cancer 61(6):303–313. https://doi.org/10.1002/gcc.22987CrossRefPubMed

19.

Li MM, Datto M, Duncavage EJ et al (2017) Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19(1):4–23. https://doi.org/10.1016/j.jmoldx.2016.10.002CrossRefPubMedPubMedCentral

20.

Haslam A, Kim MS, Prasad V (2021) Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006–2020. Ann Oncol 32(7):926–932. https://doi.org/10.1016/j.annonc.2021.04.003CrossRefPubMed

21.

Mosele F, Remon J, Mateo J et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31(11):1491–1505. https://doi.org/10.1016/j.annonc.2020.07.014CrossRefPubMed

22.

Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M (2020) When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine 25:100487. https://doi.org/10.1016/j.eclinm.2020.100487

23.

Subbiah V, Kurzrock R (2023) Universal germline and tumor genomic testing needed to win the war against cancer: genomics is the diagnosis. J Clin Oncol 41(17):3100–3103. https://doi.org/10.1200/jco.22.02833CrossRefPubMed

24.

Sorscher S. Do all patients diagnosed with cancer deserve germline testing? J Clin Oncol 41(24):4057–4058. https://doi.org/10.1200/jco.23.00710

25.

Colomer R, Miranda J, Romero-Laorden N, Hornedo J, González-Cortijo L, Mouron S, Bueno MJ, Mondéjar R, Quintela-Fandino M (2023) Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement. eClinicalMedicine 60:102029. https://doi.org/10.1016/j.eclinm.2023.102029

26.

Massard C, Michiels S, Ferté C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7(6):586–595. https://doi.org/10.1158/2159-8290.Cd-16-1396CrossRefPubMed

27.

Sicklick JK, Kato S, Okamura R et al (2019) Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 25(5):744–750. https://doi.org/10.1038/s41591-019-0407-5CrossRefPubMedPubMedCentral

28.

Rothwell DG, Ayub M, Cook N et al (2019) Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med 25(5):738–743. https://doi.org/10.1038/s41591-019-0380-zCrossRefPubMed

29.

Von Hoff DD, Stephenson JJ, Rosen P et al (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28(33):4877–4883. https://doi.org/10.1200/jco.2009.26.5983CrossRef

30.

Horak P, Heining C, Kreutzfeldt S et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11(11):2780–2795. https://doi.org/10.1158/2159-8290.Cd-21-0126CrossRefPubMed

31.

Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N (2019) Defining, identifying, and understanding “exceptional responders” in oncology using the tools of precision medicine. Cancer J 25:4CrossRef

32.

Wahida A, Buschhorn L, Fröhling S et al (2023) The coming decade in precision oncology: six riddles. Nat Rev Cancer 23(1):43–54. https://doi.org/10.1038/s41568-022-00529-3CrossRefPubMed

33.

Rosenquist R, Cuppen E, Buettner R et al (2022) Clinical utility of whole-genome sequencing in precision oncology. Semin Cancer Biol 84:32–39. https://doi.org/10.1016/j.semcancer.2021.06.018CrossRefPubMed

34.

Massard C, Michiels S, Ferté C et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. https://doi.org/10.1158/2159-8290.cd-16-1396CrossRefPubMed

35.

Adalsteinsson VA, Ha G, Freeman SS et al (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 8(1):1324. https://doi.org/10.1038/s41467-017-00965-yCrossRefPubMedPubMedCentral

36.

Riedl JM, Hasenleithner SO, Pregartner G et al (2021) Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. Ther Adv Med Oncol 13:1758835920987658. https://doi.org/10.1177/1758835920987658CrossRefPubMedPubMedCentral

37.

38.

Bayle A, Belcaid L, Aldea M et al (2023) Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. Ann Oncol 34(4):389–396. https://doi.org/10.1016/j.annonc.2023.01.008CrossRefPubMed

39.

Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71–88. https://doi.org/10.1038/s41576-018-0071-5CrossRefPubMed

40.

Parikh AR, Leshchiner I, Elagina L et al (2019) Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 25(9):1415–1421. https://doi.org/10.1038/s41591-019-0561-9CrossRefPubMedPubMedCentral

41.

Kim H, Park KU (2023) Clinical circulating tumor DNA testing for precision oncology. Cancer Res Treat 55(2):351–366. https://doi.org/10.4143/crt.2022.1026CrossRefPubMedPubMedCentral

42.

Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. https://doi.org/10.1056/NEJMoa1103782CrossRefPubMedPubMedCentral

43.

Kwak EL, Bang Y-J, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med 363(18):1693–1703. https://doi.org/10.1056/NEJMoa1006448CrossRefPubMedPubMedCentral

44.

André T, Shiu K-K, Kim TW et al (2020) Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med 383(23):2207–2218. https://doi.org/10.1056/NEJMoa2017699CrossRefPubMed

45.

Hellmann MD, Ciuleanu T-E, Pluzanski A et al (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 378(22):2093–2104. https://doi.org/10.1056/NEJMoa1801946CrossRefPubMedPubMedCentral

46.

Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15(12):731–747. https://doi.org/10.1038/s41571-018-0113-0CrossRefPubMedPubMedCentral

47.

Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated <em>BRAF</em><sup>V600E</sup>-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17(7):984–993. https://doi.org/10.1016/S1470-2045(16)30146-2CrossRefPubMedPubMedCentral

48.

Kopetz S, Grothey A, Yaeger R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med 381(17):1632–1643CrossRefPubMed

49.

Li X, Warner JL (2020) A review of precision oncology knowledgebases for determining the clinical actionability of genetic variants. Mini Review. Front Cell Dev Biol 8. https://doi.org/10.3389/fcell.2020.00048

50.

Perakis SO, Weber S, Zhou Q et al (2020) Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. ESMO Open 5(5):e000872. https://doi.org/10.1136/esmoopen-2020-000872CrossRefPubMedPubMedCentral

51.

Mateo J, Chakravarty D, Dienstmann R et al (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 29(9):1895–1902. https://doi.org/10.1093/annonc/mdy263CrossRefPubMedPubMedCentral

52.

Luchini C, Lawlor RT, Milella M, Scarpa A (2020) Molecular tumor boards in clinical practice. Trends Cancer 6(9):738–744. https://doi.org/10.1016/j.trecan.2020.05.008CrossRefPubMed

53.

Subbiah V, Kurzrock R (2018) Challenging standard-of-care paradigms in the precision oncology era. Trends Cancer 4(2):101–109. https://doi.org/10.1016/j.trecan.2017.12.004CrossRefPubMedPubMedCentral

54.

Gardner B, Doose M, Sanchez JI, Freedman AN, de Moor JS (2021) Distribution of genomic testing resources by oncology practice and rurality: a nationally representative study. JCO Precis Oncol 5:PO.21.00109. https://doi.org/10.1200/po.21.00109

55.

Horak P, Klink B, Heining C et al (2017) Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141(5):877–886. https://doi.org/10.1002/ijc.30828CrossRefPubMed

56.

Li K, Luo H, Huang L, Luo H, Zhu X (2020) Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int 20(1):16. https://doi.org/10.1186/s12935-019-1091-8CrossRefPubMedPubMedCentral

57.

Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69–74. https://doi.org/10.1126/science.aaa4971CrossRefPubMed

58.

Bonneville R, Krook MA, Kautto EA et al (2017) Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol 1:1–15. https://doi.org/10.1200/po.17.00073CrossRef

59.

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. New England J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596CrossRef

60.

Petrelli F, Ghidini M, Ghidini A, Tomasello G (2020) Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. JAMA Oncol 6(7):1068–1071. https://doi.org/10.1001/jamaoncol.2020.1046CrossRefPubMed

61.

Marabelle A, Fakih M, Lopez J et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365. https://doi.org/10.1016/s1470-2045(20)30445-9CrossRefPubMed

62.

McGrail DJ, Pilié PG, Rashid NU et al (2021) High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661–672. https://doi.org/10.1016/j.annonc.2021.02.006CrossRefPubMed

63.

Hechtman JF (2022) NTRK insights: best practices for pathologists. Mod Pathol 35(3):298–305. https://doi.org/10.1038/s41379-021-00913-8CrossRefPubMed

64.

Solomon JP, Linkov I, Rosado A et al (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 1:38–46. https://doi.org/10.1038/s41379-019-0324-7CrossRef

65.

Rosen EY, Goldman DA, Hechtman JF et al (2020) TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res 26(7):1624–1632. https://doi.org/10.1158/1078-0432.Ccr-19-3165CrossRefPubMed

66.

McDermott R, van Tilburg CM, Farago AF et al (2020) 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. Ann Oncol 31:S1101–S1102. https://doi.org/10.1016/j.annonc.2020.08.1347CrossRef

67.

Demetri GD, De Braud F, Drilon A et al (2022) Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 28(7):1302–1312. https://doi.org/10.1158/1078-0432.Ccr-21-3597CrossRefPubMedPubMedCentral

68.

Marchiò C, Scaltriti M, Ladanyi M et al (2019) ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30(9):1417–1427. https://doi.org/10.1093/annonc/mdz204CrossRefPubMed

69.

Gerstung M, Jolly C, Leshchiner I et al (2020) The evolutionary history of 2,658 cancers. Nature 578(7793):122–128. https://doi.org/10.1038/s41586-019-1907-7CrossRefPubMedPubMedCentral

70.

Adashek JJ, Kato S, Lippman SM, Kurzrock R (2020) The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med 12(1):16. https://doi.org/10.1186/s13073-020-0714-yCrossRefPubMedPubMedCentral

71.

Letai A, Bhola P, Welm AL (2022) Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40(1):26–35. https://doi.org/10.1016/j.ccell.2021.12.004CrossRefPubMed

72.

Ignatiadis M, Sledge GW, Jeffrey SS (2021) Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Rev Clin Oncol 18(5):297–312. https://doi.org/10.1038/s41571-020-00457-xCrossRefPubMed

73.

Christofyllakis K, Bittenbring JT, Thurner L et al (2022) Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Mol Clin Oncol 16(1):21. https://doi.org/10.3892/mco.2021.2453CrossRefPubMed

Title: Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view
Authors: Jakob M. Riedl
Florian Moik
Tamara Esterl
Sarah M. Kostmann
Armin Gerger
Philipp J. Jost
Publication date: 20-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Cancer Therapy
Targeted Therapy
Published in: Virchows Archiv / Issue 2/2024
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-023-03702-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review

Correction to: The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: An updated review

Genomic alterations and diagnosis of renal cancer

Molecular features for timely cancer diagnosis and treatment – tumors of the ovary, fallopian tube and endometrium

Current challenges and practical aspects of molecular pathology for non-small cell lung cancers

Diagnostic and prognostic molecular pathology of lymphoid malignancies